Source-grounded facts extracted from Theravance Biopharma, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Theravance Biopharma, Inc. shareholders approved Non-binding advisory resolution regarding the compensation of the Company’s named executive officers at the 2026-06-12 meeting.
“Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non-Votes 42,631,324 221,196 51,183 4,156,175”
Theravance Biopharma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-12 meeting.
“Proposal Two – Based on the following results of voting, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified: For Against Abstain Broker Non-Votes 46,471,340 572,896 15,642 —”
Theravance Biopharma, Inc. shareholders approved Election of Directors at the 2026-06-12 meeting.
“Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company’s Annual General Meeting held in 2027 and until their successors are duly elected and qualified: Nominees For Against Abstain Broker Non-Votes Laurie Smaldone Alsup 42,725,649 124,187 53,867 4,156,175 Susannah Gray 42,231,530 618,306 53,867 4,156,175 Dean J. Mitchell 42,557,257 297,316 49,130 4,156,175 Donal O’Connor 42,535,463 319,110 49,130 4,156,175 Deepika R. Pakianathan 41,936,019 918,543 49,141 4,156,175 Rick E Winningham 42,474,538 377,274 51,891 4,156,175”
Theravance Biopharma, Inc. reported first quarter of 2026 results: revenue $17.7 million.
“Total revenue for the first quarter of 2026 was $17.7 million, consisting entirely of Viatris collaboration revenue.”
Theravance Biopharma, Inc. reported financial results for the quarter and full year ended December 31, 2025.
“On March 19, 2026, Theravance Biopharma, Inc. (the “Company”) issued a press release regarding its financial results for the quarter and full year ended December 31, 2025 and a business update.”
Theravance Biopharma, Inc. announced a restructuring with charges of approximately $5 million to $7 million affecting R&D and G&A functions (approximately 50% of the Company’s overall workforce).
“On March 3, 2026, the Company announced an organizational restructuring (the “Restructuring”), which is intended to reduce cost base by approximately 60% (or approximately $70 million) and expected to impact approximately 50% of the Company’s overall workforce. The Restructuring will be implemented over the next two quarters, with the Company expecting to incur approximately $5 million to $7 million in one-time cash severance costs related to the Restructuring.”
Theravance Biopharma, Inc. completed a disposition involving GlaxoSmithKline Intellectual Property Development Limited for $225 million (closed 2025-05-30).
“ompany (“TBPH”) and GlaxoSmithKline Intellectual Property Development Limited, a private company limited by shares registered”
Theravance Biopharma, Inc. reported the first quarter of 2024 results: revenue Total revenue for the first quarter of 2024 was $14.5 million, net income Net loss was $11.7 million.
“Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results”
Theravance Biopharma, Inc. shareholders approved Non-binding advisory resolution regarding compensation of named executive officers at the 2024-05-08 meeting.
“Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non- Votes Number of Shares Voted 35,205,714 332,345 2,683 3,952,947”
Theravance Biopharma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-08 meeting.
“Proposal Two – Based on the following results of voting, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified: For Against Abstain Broker Non- Votes Number of Shares Voted 39,257,982 228,078 7,629 N/A”
Theravance Biopharma, Inc. shareholders approved Election of Class I directors: Eran Broshy, James Kelly, Laurie Smaldone Alsup at the 2024-05-08 meeting.
“Proposal One – Based on the following results of voting, the nominees listed below were elected Class I directors to serve as members of the Board until the Company’s Annual General Meeting held in 2026 and until their successors are duly elected and qualified: Nominees For Against Abstain Broker Non- Votes Eran Broshy 35,316,310 223,797 635 3,952,947 James Kelly 35,265,676 274,631 435 3,952,947 Laurie Smaldone Alsup 35,290,841 240,365 9,536 3,952,947”
Theravance Biopharma, Inc. reported full year ended December 31, 2023 results: revenue $57.2 million.
“· Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 million”
Theravance Biopharma, Inc. reported Q4 2023 results: net income $8.5 million.
“· GAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4, with Non-GAAP Net Profit of $1.4 million 2”
Theravance Biopharma, Inc. entered into Cooperation Agreement with Irenic Capital Management LP, Irenic Capital Management GP LLC, Irenic Capital Evergreen Master Fund LP, Irenic Capital Evergreen Fund GP LLC (effective 2023-12-21).
“On December 21, 2023, Theravance Biopharma, Inc., a Cayman Islands exempted company (the “Company”), entered into a cooperation agreement (the “Cooperation Agreement”) with Irenic Capital Management LP, a Delaware limited partnership, Irenic Capital Management GP LLC, a Delaware limited liability company, Irenic Capital Evergreen Master Fund LP, a Cayman Islands limited partnership, and Irenic Capital Evergreen Fund GP LLC, a Delaware limited liability company (collectively “Irenic”).”
Jeremy Grant was appointed as Director at Theravance Biopharma, Inc..
“In connection with the Cooperation Agreement, the New Director was appointed to the Board, as well as the Development and Commercialization Committee and the Compensation Committee, each effective December 21, 2023.”
Theravance Biopharma, Inc. reported the third quarter of 2023 results: revenue $15.7 million, net income $9.0 million.
“Total revenue for the third quarter of 2023 was $15.7 million”
Richard Graham departed as Senior Vice President, Research & Development at Theravance Biopharma, Inc..
“In connection with internal changes at Theravance Biopharma, Inc., Richard Graham, Ph.D., Senior Vice President, Research & Development will be leaving the Company on or around February 29, 2024.”
Theravance Biopharma, Inc. terminated Pfizer Agreement with Pfizer Inc. (effective 2023-10-07).
“On June 9 , 2023, the Company received notice from Pfizer terminating the Pfizer Agreement, effective as of October 7, 2023.”
Theravance Biopharma, Inc. reported the first quarter of 2023 results: revenue $10.4 million.
“Total revenue for the first quarter of 2023 was $10.4 million”
Theravance Biopharma, Inc.: Amended and restated memorandum and articles of association to declassify the board of directors over time (effective 2023-05-02).
“On May 2, 2023, at the Annual Meeting, the Company’s shareholders approved an amendment and restatement of the Company’s Amended and Restated Memorandum and Articles of Association (as amended and restated, the “Amended Memorandum and Articles”) to declassify the Company’s board of directors over time.”
Theravance Biopharma, Inc. shareholders approved Amendment to declassify the Board over time at the 2023-05-02 meeting.
“Proposal Six – Based on the following results of voting, an amendment to the Company’s Amended and Restated Memorandum and Articles of Association to declassify the Board over time was approved: For Against Abstain Broker Non-Votes Number of Shares Voted 46,475,207 1,235,783 5,806 6,086,895”
Theravance Biopharma, Inc. shareholders approved Approval of Amended and Restated 2013 Equity Incentive Plan at the 2023-05-02 meeting.
“Proposal Five – Based on the following results of voting, the Company’s Amended and Restated 2013 Equity Incentive Plan was approved: For Against Abstain Broker Non-Votes Number of Shares Voted 39,511,933 8,125,310 79,553 6,086,895”
Theravance Biopharma, Inc. shareholders approved Advisory vote on frequency of shareholder votes on executive compensation (every year) at the 2023-05-02 meeting.
“Proposal Four – Based on the following results of voting, the Company’s shareholders approved, on an advisory basis, that shareholder votes on the compensation of the Company’s named executive officers occur every year: 1 Year 2 Years 3 Years Abstain Broker Non-Votes Number of Shares Voted 46,190,946 4,671 1,498,681 22,498 6,086,895”
Theravance Biopharma, Inc. shareholders approved Non-binding advisory resolution on compensation of named executive officers at the 2023-05-02 meeting.
“Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non-Votes Number of Shares Voted 42,597,635 5,073,854 45,307 6,086,895”
Theravance Biopharma, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-02 meeting.
“Proposal Two – Based on the following results of voting, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified: For Against Abstain Broker Non-Votes Number of Shares Voted 52,773,713 928,728 101,250 N/A”
Theravance Biopharma, Inc. shareholders approved Election of Class III directors at the 2023-05-02 meeting.
“Proposal One – Based on the following results of voting, the nominees listed below were elected Class III directors to serve as members of the Board until the Company’s Annual General Meeting held in 2026 and until their successors are duly elected and qualified: Nominees For Against Abstain Broker Non-Votes Dean J. Mitchell 37,494,937 10,195,459 26,400 6,086,895 Deepika R. Pakianathan 41,984,899 5,705,313 26,584 6,086,895”
James C. Kelly was appointed as Class I member of the Board at Theravance Biopharma, Inc..
“On April 11, 2023, James C. Kelly was appointed by the Board of Directors (the “Board”) of Theravance Biopharma, Inc. (the “Company”) to serve as a Class I member of the Board for a term expiring at the Company’s Annual General Meeting of Shareholders in 2024.”
Andrew Hindman departed as Chief Financial Officer at Theravance Biopharma, Inc..
“On January 10, 2023, Theravance Biopharma US, Inc., a wholly owned subsidiary of the Company (“Theravance Biopharma US”), and Mr. Hindman entered into a separation agreement and release of claims (the “Separation Agreement”).”
William D. Young departed as Director at Theravance Biopharma, Inc..
“In addition, on February 26, 2023, William D. Young decided not to stand for re-election as a director at the Company’s next annual general meeting of shareholders.”
Susannah Gray was appointed as Director at Theravance Biopharma, Inc..
“On February 26, 2023, Susannah Gray was appointed by the Board of Directors of Theravance Biopharma, Inc. (the “Company”) to serve as a Class II member of the Board of Directors.”
Aziz Sawaf was appointed as Chief Financial Officer at Theravance Biopharma, Inc..
“The Company has appointed Aziz Sawaf, CFA as the Company’s Chief Financial Officer, effective immediately following Mr. Hindman’s departure.”
Andrew A. Hindman changed role as Senior Vice President and Chief Financial Officer at Theravance Biopharma, Inc..
“Andrew A. Hindman, Senior Vice President and Chief Financial Officer, will transition from the Company on December 31, 2022.”
Theravance Biopharma, Inc. reported third quarter of 2022 results: revenue $12.5 million.
“Revenue: Total revenue for the third quarter of 2022 was $12.5 million”
Vijay Sabesan departed as other_named_officer at Theravance Biopharma, Inc..
“On November 30, 2021, the Company and Mr. Sabesan entered into a consulting agreement to facilitate the transition of activities following Mr. Sabesan’s departure, pursuant to which certain outstanding equity awards will vest.”
Bradford Shafer resigned as EVP & General Counsel at Theravance Biopharma, Inc..
“the Company and Mr. Shafer entered into a consulting agreement to facilitate the transition of activities following Mr. Shafer’s departure”
George M. Whitesides resigned as Director at Theravance Biopharma, Inc..
“George M. Whitesides notified the Company of his resignation as a Director of the Company effective September 14, 2021”
Robert V. Gunderson, Jr. resigned as Director at Theravance Biopharma, Inc..
“Robert V. Gunderson, Jr. notified the Company of his resignation as a Director of the Company effective September 11, 2021”
Vijay Sabesan departed as Senior Vice President, Technical Operations at Theravance Biopharma, Inc..
“Vijay Sabesan, Senior Vice President, Technical Operations, a “named executive officer” from 2021, will leave the Company on November 30, 2021.”
Braford J. Shafer resigned as Executive Vice President and General Counsel at Theravance Biopharma, Inc..
“On September 13, 2021, Braford J. Shafer, a “named executive officer” from 2021, notified the Company of his resignation as its Executive Vice President and General Counsel effective on September 30, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.